- Home
- KFFB vs CMMB Comparison
KFFB vs CMMB Comparison
Compare KFFB & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFFB
- CMMB
- Stock Information
- Founded
- KFFB 2005
- CMMB 2004
- Country
- KFFB United States
- CMMB Israel
- Employees
- KFFB N/A
- CMMB N/A
- Industry
- KFFB Savings Institutions
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- KFFB Finance
- CMMB Health Care
- Exchange
- KFFB Nasdaq
- CMMB Nasdaq
- Market Cap
- KFFB 21.0M
- CMMB 23.0M
- IPO Year
- KFFB 2005
- CMMB N/A
- Fundamental
- Price
- KFFB $2.54
- CMMB $1.21
- Analyst Decision
- KFFB
- CMMB Strong Buy
- Analyst Count
- KFFB 0
- CMMB 2
- Target Price
- KFFB N/A
- CMMB $9.00
- AVG Volume (30 Days)
- KFFB 3.7K
- CMMB 89.3K
- Earning Date
- KFFB 05-12-2025
- CMMB 05-27-2025
- Dividend Yield
- KFFB N/A
- CMMB N/A
- EPS Growth
- KFFB N/A
- CMMB N/A
- EPS
- KFFB N/A
- CMMB N/A
- Revenue
- KFFB $8,308,000.00
- CMMB N/A
- Revenue This Year
- KFFB N/A
- CMMB N/A
- Revenue Next Year
- KFFB N/A
- CMMB N/A
- P/E Ratio
- KFFB N/A
- CMMB N/A
- Revenue Growth
- KFFB 13.79
- CMMB N/A
- 52 Week Low
- KFFB $2.00
- CMMB $0.60
- 52 Week High
- KFFB $3.72
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- KFFB 46.45
- CMMB 46.51
- Support Level
- KFFB $1.96
- CMMB $1.15
- Resistance Level
- KFFB $2.75
- CMMB $1.31
- Average True Range (ATR)
- KFFB 0.16
- CMMB 0.09
- MACD
- KFFB -0.00
- CMMB -0.00
- Stochastic Oscillator
- KFFB 73.42
- CMMB 22.58
About KFFB Kentucky First Federal Bancorp
Kentucky First Federal Bancorp is a holding company. The company through its subsidiaries is engaged mainly in the business of accepting deposits from the general public and using such funds to originate loans secured by first mortgages on owner-occupied, residential real estate and other loans secured by real estate. Its primary products and services include Residential mortgage loans, Multi-family loans, Construction loans and types of deposits, etc. The company mainly operates in Perry, Franklin, Boyle and Garrard and surrounding counties in Kentucky, US.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.